Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium
Flannery CA, Fleming AG, Choe GH, Naqvi H, Zhang M, Sharma A, Taylor HS. Endometrial Cancer-Associated FGF18 Expression Is Reduced by Bazedoxifene in Human Endometrial Stromal Cells In Vitro and in Murine Endometrium. Endocrinology 2016, 157: 3699-3708. PMID: 27267714, PMCID: PMC5045514, DOI: 10.1210/en.2016-1233.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAnimalsBasic Helix-Loop-Helix Transcription FactorsCarcinoma, EndometrioidCase-Control StudiesCells, CulturedEndometrial HyperplasiaEndometrial NeoplasmsEndometriumFemaleFibroblast Growth FactorsGene Expression ProfilingHumansIndolesMiceMiddle AgedSelective Estrogen Receptor ModulatorsConceptsStromal cellsPostmenopausal womenHormone therapyEpithelial proliferationFGF18 expressionAntiproliferative effectsSelective estrogen receptor modulatorsHuman endometrial stromal cellsGrowth factorBZA/CEMenopausal hormone therapyEndometrial stromal cellsBreast cancer riskEstrogen receptor modulatorsCD1 female miceE74-like factor 5Normal proliferative endometriumParacrine growth factorPrimary stromal cellsTyrosine kinase receptor 2Fibroblast growth factorEndometrial hyperplasiaEndometrial proliferationEndometrial cancerEndometrial adenocarcinoma